Table I.
Gastric Cancer Immunotherapy Trials
| Immunotherapy Trial | Trial Design | Treatment | Patients | Median PFS months (95% CI) | Median OS months (95% CI) |
Ref |
|---|---|---|---|---|---|---|
| ATTRACTION-2 | Phase III Trial 3rd line |
nivolumab vs placebo |
330 163 |
1.61 (1.54–2.30) 1.45 (1.45–1.54) |
5.26 (4.60–6.37) 4.14 (3.42–4.86) |
50 |
| NCT01585987 | Phase II Trial 2nd line |
ipilumimab vs supportive care |
57 57 |
2.92 (1.61–5.16) 4.90 (3.45–6.54) |
12.7 (10.5–18.9) 12.1 (9.3-NA) |
53 |
| KEYNOTE-158 | Phase II Trial 2nd line, MSI-H |
pembrolizumab | 24 | 11.0 (2.1-NR) | NR (7.2-NR) | 54 |
| KEYNOTE-059 | Phase II Trial 3rd line |
pembrolizumab | 259 | 2.0 (2.0–2.1) | 5.6 (4.3–6.9) | 56 |
| KEYNOTE-061 | Phase III Trial 2nd line |
pembrolizumab paclitaxel |
196 199 |
1.5 (1.4–2.0) 4.1 (3.1–4.2) |
9.1 (6.2–10.7) 8.3 (7.6–9.0) |
58 |
| JAVELIN | Phase III Trial 3rd line |
avelumab chemotherapy |
185 186 |
1.4 (1.4–1.5) 2.7 (1.8–2.8) |
4.6 (3.6–5.7) 5.0 (4.5–6.3) |
59 |
| KEYNOTE-062 | Phase III Trial 1st line PD-L1 CPS 1+ |
pembrolizumab chemotherapy pembro/chemo |
256 250 257 |
2.0 (1.5–2.8) 6.4 (5.7–7.0) 6.9 (5.7–7.3) |
10.6 (7.7–13.8) 11.1 (9.2–12.8) 12.5 (10.8– 13.9) |
60 |
| Checkmate 032 | Phase I/II 3rd line |
nivolumab 3mg/kg nivolumab 1mg/kg + ipilumumab 3mg/kg nivolumab 3mg/kg + ipilumumab 1mg/kg |
59 49 52 |
1.4 (1.2–1.5) 1.4 (1.2–3.8) 1.6 (1.4–2.6) |
6.2 (3.4–12.4) 6.9 (3.7 to 11.5) 4.8 (3.0–8.4) |
61 |
| NCT02340975 | Phase IB/II 3rd line |
durvalumab tremelimumab durval/tremel |
24 12 52 |
1.6 (1.0–1.8) 1.7 (0.8–5.3) 1.8 (1.6–3.3) |
3.4 (1.7–4.4) 7.7 (2.1–13.7) 9.2 (5.4–12.6) |
62 |
| NCT02572687 | Phase Ib 2nd line |
durvalumab + ramucirumab | 29 | 2.6 (1.5–7.1) | 12.4 (5.5–16.9) | 63 |
| KEYNOTE-659 | IIb 1st line PDL-1+ |
pembrolizumab + SOX |
54 | 9.4 (6.6–NE) | NR | 64 |